**ORIGINAL RESEARCH PAPER** 

# **INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH**

# LAPAROSCOPIC VERSUS OPEN SURGERY FOR NODE POSITIVE RECTAL CANCER: A RETROSPECTIVE ANALYSIS OF RECTAL CANCER PATIENTS IN A SINGLE INSTITUTION

Oncology								
Dr. Srinivas C	Associate Professor of Surgical oncology Department of Surgical oncology Kidwa memorial institute of oncology Bengaluru							
Dr. Pavan kumar J *	Senior resident Department of Surgical oncology Kidwai memorial institute of oncology Bengaluru *Corresponding Author							
Dr. C Ramachandra	Professor of Surgical oncology Department of Surgical oncology Kidwai memori institute of oncology Bengaluru							

## ABSTRACT

**INTRODUCTION:** Colorectal cancer is the third most common cancer and ranks second in terms of mortality. Rectal cancers are biologically aggressive. Implementation of laparoscopy in the management of rectal cancers is challenging and oncological outcomes should be comparable with open surgery before widespread application of laparoscopy. This study is performed to assess laparoscopic versus open surgery in the management of rectal cancer.

MATERIALS AND METHODS: This is a retrospective analysis of 112 patients who under went open or laparoscopic surgery for rectal cancer. Both the groups were analysed in terms of operative time and post-operative complications and oncological outcomes.

**RESULTS:** Of 112 patients with rectal cancer surgery, 53.6% (n=60) underwent open surgery and 46.4% (n=52) underwent laparoscopic surgery. The median age of patients in our study is 52 years with range 21-80 years. 60.7% were males. Conversion rate in our study is 3.6%. The major reason for conversion is bleeding. Majority belong T3, N1b, and stage IIIB. No statistically significant differences were observed between the two groups in terms of blood loss, complications, recurrence, 5-year Disease free survival (DFS) and overall survival (OS). There was a significant difference observed between the two groups in regard to operative time. Laparoscopic surgery is 40 min longer than open surgery for rectal cancer. **CONCULSION:** Laparoscopic surgery has longer operative times than open surgery. However, laparoscopic and open have comparable equal efficacy in relation to post-operative complications, oncological outcomes.

# **KEYWORDS**

### **INTRODUCTION:**

Colorectal cancer is the third most common cancer and ranks second in terms of mortality. Colorectal cancer incidence rates vary widely, with 8-fold and 6-fold variations in colon and rectal cancer varied by geographic variations. (1) Nearly one third of all large bowel cancers are located in the rectum. (2) The standard management option for non-metastatic rectal cancer is multimodal therapy that includes surgery, supported by chemoradiotherapy in neoadjuvant or adjuvant settings. (3)

The development of minimally invasive techniques that includes laparoscopy, robotic and hybrid procedures led to their application in rectal cancer. Many clinical studies proved the usefulness of laparoscopic surgery for colon cancer compared with open surgery with regard to short-term outcomes, and long-term noninferiority has also been demonstrated.

Laparoscopic rectal cancer surgery is a technically demanding procedure and thus prohibit implementation of this technique in rectal cancers and especially in low lying ones. Laparoscopic surgery for rectal cancer was stated to be more difficult than that for colon cancer, so rectal cancer had been eliminated in some studies. (4-7) Some studies demonstrated the benefit of laparoscopic surgery for rectal cancer compared with open surgery, (8,9) whereas other clinical trials did not show the noninferiority of laparoscopic surgery. (10,11)

We conducted this retrospective single institution study to compare the long-term term oncological outcomes of laparoscopic versus open surgery for rectal cancer surgery.

## MATERIALSAND METHODS:

This study involved patients with clinical stage III rectal cancer who underwent open or laparoscopic surgery at our institute undergoing open or Laparoscopic surgery for rectal cancer from 2013 to 2014. This retrospective study identified 112 patients who underwent surgery for rectal cancer. All the patients were evaluated with Contrast enhanced CT scan of abdomen and pelvis and MRI pelvis, colonoscopy. All patients underwent biopsy of the lesion and subsequent metastatic work up with chest x ray.

Patients who were diagnosed with rectal cancer were subjected to surgery when there is no involvement of circumferential margin. Circumferential margin is described as positive if the tumour extends to a point that is within 1 mm from the margin. Circumferential margin is described as threatened if the tumour extends to a point that is within 1-2 mm from the margin. Patients with positive circumferential margin underwent long course neoadjuvant capecitabine with oxaliplatin based chemoradiotherapy followed by surgery after 6 weeks. Patients with threatened circumferential margin underwent short course radiotherapy followed by surgery after 5 days but within 14 days.

Patients with diagnosis of rectal cancer between ages 18 to 80 years, histologically confirmed invasive adenocarcinoma were included in the study. Patients having distant metastases, presenting as acute obstruction and those who had medical complications precluding laparoscopic surgery were excluded from the study.

All surgeries were performed by the same surgical team that had extensive experience with open and laparoscopic colorectal surgery. All patients had mechanical bowel preparation with sodium phosphate. For laparoscopic resections, pneumoperitoneum with an intra-abdominal pressure between 12 and 14 mmHg was continued throughout the operation. The first step of the laparoscopic operation is dissection of the colon from medial to lateral and vessel ligation. In the left colon and rectum operations, distal resection is performed laparoscopically and proximal end is taken out from the suprapubic incision. After placing the anvil outside, anastomosis is performed intracorporeally. Care was taken to deliver the specimen under protection. A no-touch technique was also used in the open group. Anterior or low anterior resection is performed in rectum tumours according to the localization. Abdominoperineal resection was performed when there is sphincter involvement in low rectal cancer. Temporary ileostomy is mostly performed in low anterior resection cases. Patients in both groups underwent routine operation according to the complete mesocolic or mesorectal excision principles.

The demographic and clinicopathological data of consecutive patients were collected retrospectively, including the ECOG performance status, preoperative chemoradiotherapy, operative time, blood loss, conversion, tumour pathology, length of hospital stays, postoperative complications, recurrence-free survival (RFS), and overall survival (OS) periods. Statistical analysis was performed using SPSS software and p value <0.05 is considered statistically significant.

## **RESULTS:**

Of 112 patients with rectal cancer surgery, 53.6% (n=60) underwent open surgery and 46.4% (n=52) underwent laparoscopic surgery. Demographic variables are depicted in table 1 and Staging characters are tabulated in table 2. The median age of patients in our study is 52 years with range 21-80 years. 60.7% were males. Conversion rate in our study is 3.6%. The major reason for conversion is bleeding.

Majority belong T3, N1b, and stage IIIB. The data regarding Operative time, blood loss, complications, recurrence, 5-year Disease free survival (DFS) and Over all survival (OS) were depicted in tables 3-6 respectively.

Our study showed significant difference in the operative time between the laparoscopy and open groups. (140 minutes versus 174 minutes; 31.5 pearson chi-square p value <0.001)

Our study showed that circumferential margin positivity is observed in 15% of open surgery group and 8.3% of the laparoscopy group. (p value 0.183; chi-square 1.45)

No statistically significant differences were observed between the two groups in terms of blood loss, complications, recurrence, 5-year Disease free survival (DFS) and overall survival (OS).

Variable         OPEN (n=60)         LAP (n=52)           Age (Median)         52 years         50 years           Sex - Male         31.25% (n=35)         29.4% (n=33)           Sex - Female         22.3% (n=25)         16.9% (n=40)           Histology - Adeno         41.9% (n=47)         35.7% (n=40)           Histology - signet ring         11.6% (n=13)         10.7% (n=12)           Location - Upper         3.5% (n=4)         4.4% (n=5)           Location - Lower         35.7% (n=40)         28.5% (n=32)           Grade - Well         27.67% (n=31)         22.3% (n=25)           Grade - moderate         12.5% (n=14)         12.5% (n=14)           Grade - Poor         13.3% (n=15)         11.6% (n=13)           Pre op CT - YES         16.07% (n=18)         8.9% (n=10)           Pre op RT - NO         36.6% (n=41)         35.7% (n=42)           Pre op RT - NO         36.6% (n=41)         35.7% (n=40)           Table 2: Staging variables         Variable         OPEN (n=60)         LAP (n=52)           T1         0.89% (n=1)         1.7% (n=2)         12.7% (n=2)           T2         15.17% (n=17)         10.7% (n=12)         12.7% (n=3)           T3         19.6% (n=22)         23.2% (n=6-6) <td< th=""><th>Table 1: Demog</th><th>rap</th><th>hic va</th><th>riables</th><th></th><th></th><th></th><th></th><th></th><th></th></td<>	Table 1: Demog	rap	hic va	riables									
Age (Median)         52 years         50 years           Sex - Male         31.25% (n=35)         29.4% (n=33)           Sex - Female         22.3% (n=25)         16.9% (n=19)           Histology - Adeno         41.9% (n=47)         35.7% (n=40)           Histology - signet ring         11.6% (n=13)         10.7% (n=12)           Location - Upper         3.5% (n=4)         4.4% (n=5)           Location - Lower         35.7% (n=40)         28.5% (n=32)           Grade - Well         27.67% (n=14)         12.5% (n=14)           Grade - Well         27.67% (n=13)         22.3% (n=22)           Grade - Poor         13.3% (n=15)         11.6% (n=13)           Pre op CT - YES         16.07% (n=18)         8.9% (n=10)           Pre op RT - NO         37.5% (n=42)         37.5% (n=42)           Pre op RT - NO         36.6% (n=41)         35.7% (n=40)           Table 2: Staging variables         Variable         OPEN (n=60)         LAP (n=52)           T1         0.89% (n=1)         1.7% (n=2)         12           T2         15.17% (n=16)         8.03% (n=9)         14           T4         14.2% (n=16)         8.03% (n=9)         14           T4         14.2% (n=16)         16.07% (n=18)         12 <td></td> <td><u> </u></td> <td></td> <td colspan="3"></td> <td>LAI</td> <td colspan="4">LAP (n=52)</td>		<u> </u>					LAI	LAP (n=52)					
Sex - Male         31.25% (n=35)         29.4% (n=33)           Sex - Female         22.3% (n=25)         16.9% (n=19)           Histology - Adeno         41.9% (n=47)         35.7% (n=40)           Histology - Signet ring         11.6% (n=13)         10.7% (n=40)           Histology - Mdeno         41.9% (n=47)         35.7% (n=40)           Location - Upper         35.7% (n=40)         28.5% (n=32)           Grade - Moll         27.67% (n=31)         22.3% (n=25)           Grade - Moerate         12.5% (n=14)         12.5% (n=14)           Grade - Poor         13.3% (n=15)         11.6% (n=13)           Pre op CT - YES         16.07% (n=18)         8.9% (n=10)           Pre op CT - NO         37.5% (n=42)         37.5% (n=40)           Pre op RT - YES         16.9% (n=19)         10.7% (n=12)           Pre op RT - NO         36.6% (n=41)         35.7% (n=40)           Table 2: Staging variables         Variable         OPEN (n=60)         LAP (n=52)           T1         0.89% (n=1)         1.7% (n=2)         12           T3         19.6% (n=22)         23.2% (n=26)           T4a         14.2% (n=16)         8.03% (n=9)           T4a         2.6% (n=3)         0.89% (n=1)           N1a													
Sex – Female         22.3% (n=25)         16.9% (n=19)           Histology – Adeno         41.9% (n=47)         35.7% (n=40)           Histology – signet ring         11.6% (n=13)         10.7% (n=12)           Location – Upper         3.5% (n=4)         4.4% (n=5)           Location – Lower         35.7% (n=40)         28.5% (n=32)           Grade – Well         27.67% (n=31)         22.3% (n=25)           Grade – Moderate         12.5% (n=14)         12.5% (n=14)           Grade – Poor         13.3% (n=15)         11.6% (n=13)           Pre op CT – YES         16.07% (n=18)         8.9% (n=10)           Pre op CT – NO         37.5% (n=42)         37.5% (n=42)           Pre op RT – NO         36.6% (n=19)         10.7% (n=2)           Pre op RT – NO         36.6% (n=11)         1.7% (n=2)           T1         0.89% (n=1)         1.7% (n=2)           T2         15.17% (n=17)         10.7% (n=12)           T3         19.6% (n=22)         23.2% (n=26)           T4a         14.2% (n=16)         8.03% (n=9)           T4b         3.5% (n=31)         31.2% (n=23)           N2a         14.2% (n=16)         16.07% (n=18)           N2a         14.2% (n=16)         16.07% (n=18)	Sex – Male												
Histology – Adeno       41.9% (n=47)       35.7% (n=40)         Histology – signet ring       11.6% (n=13)       10.7% (n=12)         Location – Upper       3.5% (n=4)       4.4% (n=5)         Location – Lower       35.7% (n=40)       28.5% (n=32)         Grade – Well       27.67% (n=31)       22.3% (n=25)         Grade – moderate       12.5% (n=14)       12.5% (n=14)         Grade – Poor       13.3% (n=15)       11.6% (n=13)         Pre op CT – YES       16.07% (n=18)       8.9% (n=10)         Pre op CT – NO       37.5% (n=42)       37.5% (n=42)         Pre op RT – YES       16.9% (n=19)       10.7% (n=2)         Pre op RT – NO       36.6% (n=41)       35.7% (n=40)         Table 2: Staging variables       Variable       OPEN (n=60)       LAP (n=52)         T1       0.89% (n=1)       1.7% (n=2)       12         T2       15.17% (n=16)       8.03% (n=9)       144         T4a       14.2% (n=16)       8.03% (n=9)       144         N1a       2.6% (n=3)       0.89% (n=1)       1.7% (n=5)         N1a       2.6% (n=1)       31.2% (n=5)       1.8% (n=5)         N2a       14.2% (n=16)       16.07% (n=18)       N2a         N2b       6.25% (n=7	Sex – Female			· · · · · ·									
Histology - signet ring       11.6% (n=13)       10.7% (n=12)         Location - Upper $3.5\%$ (n=4) $4.4\%$ (n=5)         Location - Middle $14.2\%$ (n=16) $13.3\%$ (n=15)         Location - Lower $35.7\%$ (n=40) $28.5\%$ (n=32)         Grade - Well $27.67\%$ (n=31) $22.3\%$ (n=25)         Grade - Moderate $12.5\%$ (n=14) $12.5\%$ (n=14)         Grade - Poor $13.3\%$ (n=15) $11.6\%$ (n=13)         Pre op CT - YES $16.07\%$ (n=18) $8.9\%$ (n=10)         Pre op RT - NO $37.5\%$ (n=42) $37.5\%$ (n=42)         Pre op RT - NO $36.6\%$ (n=19) $10.7\%$ (n=12)         Pre op RT - NO $36.6\%$ (n=17) $10.7\%$ (n=12)         T3 $19.6\%$ (n=22) $23.2\%$ (n=26)         T4a $14.2\%$ (n=16) $8.03\%$ (n=9)         T4b $3.5\%$ (n=4) $2.6\%$ (n=3)         N1a $2.6\%$ (n=31) $31.2\%$ (n=35)         Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)         Stage III B $27.6\%$ (n=31) $31.2\%$ (n=35)         Stage III C $12.5\%$ (n=14) $8.03\%$ (n=9)         Table 3: Operative time, blood loss, complications       No10         Ma													
Location - Upper $3.5\%$ (n=4) $4.4\%$ (n=5)           Location - Middle $14.2\%$ (n=16) $13.3\%$ (n=15)           Location - Lower $35.7\%$ (n=40) $28.5\%$ (n=32)           Grade - Well $27.67\%$ (n=31) $22.3\%$ (n=25)           Grade - Moderate $12.5\%$ (n=14) $12.5\%$ (n=14)           Grade - Poor $13.3\%$ (n=15) $11.6\%$ (n=13)           Pre op CT - YES $16.07\%$ (n=18) $8.9\%$ (n=10)           Pre op RT - NO $37.5\%$ (n=42) $37.5\%$ (n=42)           Pre op RT - NO $36.6\%$ (n=19) $10.7\%$ (n=12)           Pre op RT - NO $36.6\%$ (n=17) $10.7\%$ (n=2)           T2 $15.17\%$ (n=17) $10.7\%$ (n=2)           T2 $15.17\%$ (n=17) $10.7\%$ (n=2)           T3 $19.6\%$ (n=22) $23.2\%$ (n=26)           T4a $14.2\%$ (n=16) $8.03\%$ (n=9)           T4b $3.5\%$ (n=4) $2.6\%$ (n=3)           N1a $2.6\%$ (n=3) $0.89\%$ (n=1)           N1b $30.3\%$ (n=14) $30.5\%$ (n=2)           N2a $14.2\%$ (n=16) $16.07\%$ (n=18)           N2b $6.25\%$ (n=14)	Histology – sign												
Location – Middle         14.2% (n=16)         13.3% (n=15)           Location – Lower         35.7% (n=40)         28.5% (n=32)           Grade – Well         27.67% (n=14)         22.3% (n=25)           Grade – moderate         12.5% (n=14)         12.5% (n=14)           Grade – Poor         13.3% (n=15)         11.6% (n=13)           Pre op CT – YES         16.07% (n=18)         8.9% (n=10)           Pre op RT – NO         36.6% (n=41)         35.7% (n=42)           Pre op RT – NO         36.6% (n=41)         35.7% (n=40)           Table 2: Staging variables         Variable         VPEN (n=10)         LAP (n=52)           T1         0.89% (n=1)         1.7% (n=20)         T2         15.17% (n=17)         10.7% (n=12)           T2         15.17% (n=17)         10.7% (n=12)         T3         19.6% (n=22)         23.2% (n=26)           T4a         14.2% (n=16)         8.03% (n=9)         T4b         3.5% (n=3)         0.89% (n=1)           N1b         30.3% (n=34)         2.6% (n=3)         Na9% (n=1)         N1b         30.3% (n=4)           N2a         14.2% (n=16)         16.07% (n=18)         N2b         6.25% (n=7)         4.4% (n=5)           Stage III A         13.3% (n=15)         7.1% (n=8)         Stage	Location - Uppe	3											
Location - Lower $35.7\%$ (n=40) $28.5\%$ (n=32)           Grade - Well $27.67\%$ (n=31) $22.3\%$ (n=25)           Grade - moderate $12.5\%$ (n=14) $12.5\%$ (n=14)           Grade - Poor $13.3\%$ (n=15) $11.6\%$ (n=13)           Pre op CT - YES $16.07\%$ (n=18) $8.9\%$ (n=10)           Pre op RT - YES $16.9\%$ (n=19) $10.7\%$ (n=42)           Pre op RT - NO $36.6\%$ (n=41) $35.7\%$ (n=40)           Table 2: Staging variables         Variable         OPEN (n=60)         LAP (n=52)           T1 $0.89\%$ (n=17) $10.7\%$ (n=2) $73.2\%$ (n=26)           T4a $14.2\%$ (n=16) $8.03\%$ (n=9) $74b$ $3.5\%$ (n=3) $0.89\%$ (n=1) $1.7\%$ (n=5)           N1a $2.6\%$ (n=3) $0.89\%$ (n=1)           N1b $30.3\%$ (n=15) $7.1\%$ (n=8)           Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)           Stage III B $27.6\%$ (n=31) $31.2\%$ (n=35)           Stage III B $27.6\%$ (n=60)         LAP (n=52)           P value         OPEN (n=60)         LAP (n=52)         P value           Operative time, blood loss, complicatio				14.2% (n=16)									
Grade - moderate         12.5% (n=14)         12.5% (n=14)           Grade - Poor         13.3% (n=15)         11.6% (n=13)           Pre op CT - YES         16.07% (n=18)         8.9% (n=10)           Pre op RT - YES         16.9% (n=19)         10.7% (n=42)           Pre op RT - YES         16.9% (n=19)         10.7% (n=12)           Pre op RT - NO         36.6% (n=41)         35.7% (n=40)           Table 2: Staging variables         Variable         OPEN (n=60)         LAP (n=52)           T1         0.89% (n=1)         1.7% (n=2)         12           T2         15.17% (n=17)         10.7% (n=2)         12           T3         19.6% (n=22)         23.2% (n=26)         14a           T4a         14.2% (n=16)         8.03% (n=9)         14b           T4b         3.5% (n=3)         0.89% (n=1)         N1a           N1a         2.6% (n=3)         0.89% (n=23)         N2a           N2a         14.2% (n=16)         16.07% (n=35)         Stage III A         13.3% (n=15)         7.1% (n=8)           Stage III A         13.3% (n=15)         7.1% (n=8)         Stage III C         12.5% (n=14)         8.03% (n=9)           Table 3: Operative time, blood loss, complications         Nange 121-243 minutes         0.0001	Location - Lowe	3	35.7% (n=40)				28.5% (n=32)						
Grade - Poor $13.3\%$ (n=15) $11.6\%$ (n=13)         Pre op CT - YES $16.07\%$ (n=18) $8.9\%$ (n=10)         Pre op RT - YES $16.9\%$ (n=19) $10.7\%$ (n=12)         Pre op RT - YES $16.9\%$ (n=19) $10.7\%$ (n=12)         Pre op RT - NO $36.6\%$ (n=41) $35.7\%$ (n=40)         Table 2: Staging variables         Variable       OPEN (n=60)       LAP (n=52)         T1 $0.89\%$ (n=17) $10.7\%$ (n=12)         T3 $19.6\%$ (n=2) $23.2\%$ (n=26)         T4a $14.2\%$ (n=16) $8.03\%$ (n=9)         T4b $3.5\%$ (n=4) $2.6\%$ (n=3)         N1a $2.6\%$ (n=3) $0.89\%$ (n=1)         N1b $30.3\%$ (n=34) $20.5\%$ (n=23)         N2a $14.2\%$ (n=16) $16.07\%$ (n=18)         N2b $6.25\%$ (n=7) $4.4\%$ (n=5)         Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)         Stage III B $27.6\%$ (n=31) $31.2\%$ (n=5)         Stage III C $12.5\%$ (n=60)       LAP (n=52)       P value         Operative time, blood loss, complications       Immutes       immutes       immutes         Variable       OPEN (n=60) <t< td=""><td colspan="3"></td><td colspan="4"></td><td colspan="4">22.3% (n=25)</td></t<>								22.3% (n=25)					
Pre op CT - YES       16.07% (n=18)       8.9% (n=10)         Pre op CT - NO       37.5% (n=42)       37.5% (n=42)         Pre op RT - YES       16.9% (n=19)       10.7% (n=12)         Pre op RT - NO       36.6% (n=41)       35.7% (n=40)         Table 2: Staging variables         Variable       OPEN (n=60)       LAP (n=52)         T1       0.89% (n=1)       1.7% (n=2)         T2       15.17% (n=17)       10.7% (n=2)         T3       19.6% (n=22)       23.2% (n=26)         T4a       14.2% (n=16)       8.03% (n=9)         T4b       3.5% (n=4)       2.6% (n=3)         N1a       2.6% (n=3)       0.89% (n=1)         N1b       30.3% (n=34)       20.5% (n=23)         N2a       14.2% (n=16)       16.07% (n=18)         N2b       6.25% (n=7)       4.4% (n=5)         Stage III A       13.3% (n=15)       7.1% (n=8)         Stage III B       27.6% (n=31)       31.2% (n=35)         Stage III C       12.5% (n=14)       8.03% (n=9)         Table 3: Operative time, blood loss, complications       Variable         Operative time       140 minutes       174 minutes       0.0001         (mean)       Range 136-302       minut	Grade - moderat	1	12.5% (n=14)										
Pre op CT - NO $37.5\% (n=42)$ $37.5\% (n=42)$ Pre op RT - YES $16.9\% (n=19)$ $10.7\% (n=12)$ Pre op RT - NO $36.6\% (n=41)$ $35.7\% (n=40)$ Table 2: Staging variables         Variable       OPEN (n=60)       LAP (n=52)         T1 $0.89\% (n=1)$ $1.7\% (n=2)$ T2 $15.17\% (n=17)$ $10.7\% (n=12)$ T3 $19.6\% (n=22)$ $23.2\% (n=26)$ T4a $14.2\% (n=16)$ $8.03\% (n=9)$ T4b $3.5\% (n=4)$ $2.6\% (n=3)$ N1a $2.6\% (n=3)$ $0.89\% (n=1)$ N1b $30.3\% (n=34)$ $20.5\% (n=23)$ N2a $14.2\% (n=16)$ $16.07\% (n=18)$ N2b $6.25\% (n=7)$ $4.4\% (n=5)$ Stage III A $13.3\% (n=15)$ $7.1\% (n=8)$ Stage III B $27.6\% (n=31)$ $31.2\% (n=35)$ Stage III B $27.6\% (n=60)$ LAP (n=52)       P value         Operative time       Id0 minutes $174 minutes$ $0.0001$ Quariable       OPEN (n=60)       LAP (n=52)       P value         Operative time $140 \min anage 50-650 m1$ <	Grade - Poor			13.3% (n=15)									
Pre op RT - YES       16.9% (n=19)       10.7% (n=12)         Pre op RT - NO       36.6% (n=41)       35.7% (n=40)         Table 2: Staging variables         Variable       OPEN (n=60)       LAP (n=52)         T1       0.89% (n=1)       1.7% (n=2)         T2       15.17% (n=17)       10.7% (n=2)         T3       19.6% (n=22)       23.2% (n=26)         T4a       14.2% (n=16)       8.03% (n=9)         T4b       3.5% (n=4)       2.6% (n=3)         N1a       2.6% (n=3)       0.89% (n=1)         N1b       30.3% (n=34)       20.5% (n=23)         N2a       14.2% (n=16)       16.07% (n=18)         N2b       6.25% (n=7)       4.4% (n=5)         Stage III A       13.3% (n=15)       7.1% (n=8)         Stage III B       27.6% (n=31)       31.2% (n=35)         Stage III C       12.5% (n=14)       8.03% (n=9)         Table 3: Operative time, blood loss, complications         Variable       OPEN (n=60)       LAP (n=52)       P value         Operative time       140 minutes       (mean)       Range 136-302       0.0001         Range 121-243       Range 136-302       minutes       0.006       0.006       0.006	Pre op CT – YES	S		16.07% (n=18)				8.9% (n=10)					
Pre op RT – NO $36.6\% (n=41)$ $35.7\% (n=40)$ Table 2: Staging variables         Variable       OPEN (n=60)       LAP (n=52)         T1 $0.89\% (n=1)$ $1.7\% (n=2)$ T2 $15.17\% (n=17)$ $10.7\% (n=2)$ T3 $19.6\% (n=22)$ $23.2\% (n=26)$ T4a $14.2\% (n=16)$ $8.03\% (n=9)$ T4b $3.5\% (n=4)$ $2.6\% (n=3)$ N1a $2.6\% (n=3)$ $0.89\% (n=1)$ N1b $30.3\% (n=34)$ $20.5\% (n=23)$ N2a $14.2\% (n=16)$ $16.07\% (n=18)$ N2b $6.25\% (n=7)$ $4.4\% (n=5)$ Stage III A $13.3\% (n=15)$ $7.1\% (n=8)$ Stage III B $27.6\% (n=31)$ $31.2\% (n=35)$ Stage III C $12.5\% (n=14)$ $8.03\% (n=9)$ Table 3: Operative time, blood loss, complications         Variable       OPEN (n=60)       LAP (n=52)       P value         Operative time $140 \min us$ $(mean)$ $(mean)$ $(mean)$ Range 121-243       Range 136-302 $minutes$ $0.0001$ Complications-VES $18$ $8$	Pre op CT – NO			37.5% (n=42)				37.5% (n=42)					
Table 2: Staging variables         Variable       OPEN (n=60)       LAP (n=52)         T1 $0.89\%$ (n=1) $1.7\%$ (n=2)         T2 $15.17\%$ (n=17) $10.7\%$ (n=2)         T3 $19.6\%$ (n=22) $23.2\%$ (n=26)         T4a $14.2\%$ (n=16) $8.03\%$ (n=9)         T4b $3.5\%$ (n=4) $2.6\%$ (n=3)         N1a $2.6\%$ (n=3) $0.89\%$ (n=1)         N1b $30.3\%$ (n=34) $20.5\%$ (n=23)         N2a $14.2\%$ (n=16) $16.07\%$ (n=18)         N2b $6.25\%$ (n=7) $4.4\%$ (n=5)         Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)         Stage III B $27.6\%$ (n=31) $31.2\%$ (n=35)         Stage III C $12.5\%$ (n=14) $8.03\%$ (n=9)         Table 3: Operative time, blood loss, complications $Variable$ $0PEN$ (n=60)       LAP (n=52)       P value         Operative time $140$ minutes $174$ minutes $0.0001$ (mean) $0.0001$ Range 121-243       Range 136-302       minutes $0.006$ $Complications-VES$ $18$ $0.06$ Complications-VES $18$ $8$ $0.066$ $0.066$				16.9% (n=19)				10.7% (n=12)					
Variable         OPEN (n=60)         LAP (n=52)           T1         0.89% (n=1)         1.7% (n=2)           T2         15.17% (n=17)         10.7% (n=12)           T3         19.6% (n=22)         23.2% (n=26)           T4a         14.2% (n=16)         8.03% (n=9)           T4b         3.5% (n=4)         2.6% (n=3)           N1a         2.6% (n=3)         0.89% (n=1)           N1b         30.3% (n=34)         20.5% (n=23)           N2a         14.2% (n=16)         16.07% (n=18)           N2b         6.25% (n=7)         4.4% (n=5)           Stage III A         13.3% (n=15)         7.1% (n=8)           Stage III B         27.6% (n=31)         31.2% (n=35)           Stage III C         12.5% (n=14)         8.03% (n=9)           Table 3: Operative time, blood loss, complications         Variable         OPEN (n=60)           Operative time         140 minutes         174 minutes         0.0001           Range 121-243         Range 136-302         minutes         174 minutes           Blood loss         125 ml (median)         200 ml (median)         0.008           Complications-NO         42         44         44           Table 4: Recurrence         Variable	Pre op RT – NO		3	36.6% (n	=41	)	35.7	35.7% (n=40)					
Variable         OPEN (n=60)         LAP (n=52)           T1         0.89% (n=1)         1.7% (n=2)           T2         15.17% (n=17)         10.7% (n=12)           T3         19.6% (n=22)         23.2% (n=26)           T4a         14.2% (n=16)         8.03% (n=9)           T4b         3.5% (n=4)         2.6% (n=3)           N1a         2.6% (n=3)         0.89% (n=1)           N1b         30.3% (n=34)         20.5% (n=23)           N2a         14.2% (n=16)         16.07% (n=18)           N2b         6.25% (n=7)         4.4% (n=5)           Stage III A         13.3% (n=15)         7.1% (n=8)           Stage III B         27.6% (n=31)         31.2% (n=35)           Stage III C         12.5% (n=14)         8.03% (n=9)           Table 3: Operative time, blood loss, complications         Variable         OPEN (n=60)           Operative time         140 minutes         174 minutes         0.0001           Range 121-243         Range 136-302         minutes         174 minutes           Blood loss         125 ml (median)         200 ml (median)         0.008           Complications-NO         42         44         44           Table 4: Recurrence         Variable	Table 2: Staging variables												
T2       15.17% (n=17)       10.7% (n=12)         T3       19.6% (n=22)       23.2% (n=26)         T4a       14.2% (n=16)       8.03% (n=9)         T4b       3.5% (n=4)       2.6% (n=3)         N1a       2.6% (n=3)       0.89% (n=1)         N1b       30.3% (n=34)       20.5% (n=23)         N2a       14.2% (n=16)       16.07% (n=18)         N2b       6.25% (n=7)       4.4% (n=5)         Stage III A       13.3% (n=15)       7.1% (n=8)         Stage III B       27.6% (n=31)       31.2% (n=35)         Stage III C       12.5% (n=14)       8.03% (n=9)         Table 3: Operative time, blood loss, complications       0.0001         Variable       OPEN (n=60)       LAP (n=52)       P value         Operative time       140 minutes       (mean)       0.0001         Range 121-243       Range 136-302       minutes       0.0001         Complications-VES       18       8       0.006         Complications-VES       18       8       0.006         Complications-NO       42       44       44         Table 4: Recurrence       17       0.552         Recurrence-YES       20       17       0.552	Variable O			PEN (n=60)				LAP (n=52)					
T3       19.6% (n=22)       23.2% (n=26)         T4a       14.2% (n=16) $8.03\%$ (n=9)         T4b $3.5\%$ (n=4) $2.6\%$ (n=3)         N1a $2.6\%$ (n=3) $0.89\%$ (n=1)         N1b $30.3\%$ (n=34) $20.5\%$ (n=23)         N2a $14.2\%$ (n=16) $16.07\%$ (n=18)         N2b $6.25\%$ (n=7) $4.4\%$ (n=5)         Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)         Stage III B $27.6\%$ (n=31) $31.2\%$ (n=35)         Stage III C $12.5\%$ (n=14) $8.03\%$ (n=9)         Table 3: Operative time, blood loss, complications $Variable$ $OPEN$ (n=60) $LAP$ (n=52) $P$ value         Operative time $140$ minutes $174$ minutes $0.0001$ (mean)       Range 136-302       minutes       minutes         Blood loss $125$ ml (median) $200$ ml (median) $0.006$ Complications-VES $18$ $8$ $0.066$ Complications-NO $42$ $44$ $44$ Table 4: Recurrence $177$ $0.552$ Recurrence-YES $20$ $17$ $0.552$ Recurrence-NO				0.89% (n=1)				1.7% (n=2)					
T4a       14.2% (n=16) $8.03\%$ (n=9)         T4b $3.5\%$ (n=4) $2.6\%$ (n=3)         N1a $2.6\%$ (n=3) $0.89\%$ (n=1)         N1b $30.3\%$ (n=34) $20.5\%$ (n=23)         N2a $14.2\%$ (n=16) $16.07\%$ (n=18)         N2b $6.25\%$ (n=7) $4.4\%$ (n=5)         Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)         Stage III B $27.6\%$ (n=14) $8.03\%$ (n=9)         Table 3: Operative time, blood loss, complications       Variable       OPEN (n=60)         Variable       OPEN (n=60)       LAP (n=52)       P value         Operative time       140 minutes       (mean)       Range 136-302       0.0001         Range 121-243       Range 136-302       minutes       0.0001       0.0001         Complications-VES       18       8       0.006       0.0001         Complications-NO       42       44       44       44         Table 4: Recurrence       17       0.552       0.552         Recurrence-YES       20       17       0.552       0.552         Recurrence-NO       40       35       552       552         Variable       Estimate       95% CI (UL)	T2	15.1	15.17% (n=17)				10.7% (n=12)						
T4b $3.5\% (n=4)$ $2.6\% (n=3)$ N1a $2.6\% (n=3)$ $0.89\% (n=1)$ N1b $30.3\% (n=34)$ $20.5\% (n=23)$ N2a $14.2\% (n=16)$ $16.07\% (n=18)$ N2b $6.25\% (n=7)$ $4.4\% (n=5)$ Stage III A $13.3\% (n=15)$ $7.1\% (n=8)$ Stage III B $27.6\% (n=31)$ $31.2\% (n=35)$ Stage III C $12.5\% (n=14)$ $8.03\% (n=9)$ Table 3: Operative time, blood loss, complications       Variable       OPEN (n=60)         Variable       OPEN (n=60)       LAP (n=52)       P value         Operative time       140 minutes $(174 \text{ minutes})$ $0.0001$ (mean)       Range 121-243       Range 136-302       minutes         Blood loss $125 \text{ ml}$ (median) $200 \text{ ml}$ (median) $0.08$ Complications-VES $18$ $8$ $0.06$ Complications-NO $42$ $44$ $44$ Table 4: Recurrence $Variable$ $OPEN (n=60)$ $LAP (n=52)$ $P$ value         Recurrence-YES $20$ $17$ $0.552$ $Aecorrence-YES$ $Aecorrence-YES$ $Aecorrence-YES$	T3		19.6% (n=22)										
N1a $2.6\%$ (n=3) $0.89\%$ (n=1)         N1b $30.3\%$ (n=34) $20.5\%$ (n=23)         N2a $14.2\%$ (n=16) $16.07\%$ (n=18)         N2b $6.25\%$ (n=7) $4.4\%$ (n=5)         Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)         Stage III B $27.6\%$ (n=14) $8.03\%$ (n=9)         Table 3: Operative time, blood loss, complications         Variable       OPEN (n=60)       LAP (n=52)       P value         Operative time       140 minutes $174$ minutes $0.0001$ (mean)         Range 121-243       minutes       minutes $0.0001$ Mange 121-243       minutes $0.0001$ $0.008$ Complications-YES 18       8 $0.06$ $0.06$ Complications-NO       42       44 $44$ Table 4: Recurrence $Variable$ OPEN (n=60)       LAP (n=52)       P value         Recurrence-YES       20       17 $0.552$ $0.06$ Complications-NO       40       35 $17$ $0.552$ Recurrence-NO       40 $35$ $17$ $0.552$ Recurrence-NO $40$ $35$		14.2											
N1b         30.3% (n=34)         20.5% (n=23)           N2a         14.2% (n=16)         16.07% (n=18)           N2b         6.25% (n=7)         4.4% (n=5)           Stage III A         13.3% (n=15)         7.1% (n=8)           Stage III B         27.6% (n=31)         31.2% (n=35)           Stage III C         12.5% (n=14)         8.03% (n=9)           Table 3: Operative time, blood loss, complications         Variable         OPEN (n=60)         LAP (n=52)         P value           Operative time         140 minutes         174 minutes         0.0001         (mean)           Range 121-243         minutes         minutes         0.0001           Blood loss         125 ml (median)         200 ml (median)         0.08           Complications-VES 18         8         0.06         0.006           Complications-NO         42         44         44           Table 4: Recurrence         P value         P value           Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         5	T4b 3			.5% (n=4) 2									
N2a       14.2% (n=16)       16.07% (n=18)         N2b $6.25\%$ (n=7) $4.4\%$ (n=5)         Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)         Stage III B $27.6\%$ (n=31) $31.2\%$ (n=35)         Stage III C $12.5\%$ (n=14) $8.03\%$ (n=9)         Table 3: Operative time, blood loss, complications         Variable       OPEN (n=60)       LAP (n=52)       P value         Operative time       140 minutes $174$ minutes $0.0001$ (mean)         Range 121-243       Range 136-302       minutes $0.0001$ Blood loss $125 \text{ ml}$ (median) $200 \text{ ml}$ (median) $0.08$ Complications-YES 18       8 $0.06$ $0.06$ Complications-NO       42       44 $44$ $44$ Table 4: Recurrence         Variable       OPEN (n=60)       LAP (n=52)       P value         Recurrence-YES       20       17 $0.552$ Recurrence-YES       20       17 $0.552$ Recurrence-NO       40       35 $5$ Table 5: DFS       Variable       Estimate $95\%$ CI (UL) $95\%$ CI (LL) $0.524$ <td colspan="3">N1a 2.</td> <td colspan="4">6% (n=3) 0</td> <td colspan="4">\</td>	N1a 2.			6% (n=3) 0				\					
N2b $6.25\%$ (n=7) $4.4\%$ (n=5)           Stage III A $13.3\%$ (n=15) $7.1\%$ (n=8)           Stage III B $27.6\%$ (n=31) $31.2\%$ (n=35)           Stage III C $12.5\%$ (n=14) $8.03\%$ (n=9)           Table 3: Operative time, blood loss, complications           Variable         OPEN (n=60)         LAP (n=52)         P value           Operative time         140 minutes $174$ minutes $0.0001$ (mean)           Range 121-243         Range 136-302         minutes $0.0001$ Blood loss         125 ml (median)         200 ml (median) $0.08$ Complications-YES 18         8 $0.06$ Complications-NO         42         44 $44$ Table 4: Recurrence           Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17 $0.552$ Recurrence-YES         20         17 $0.552$ Recurrence-NO         40         35 $5$ Table 5: DFS           Variable         Estimate $95\%$ CI (UL) $95\%$ CI (LL)         P value <td colspan="3"></td> <td colspan="4"></td> <td colspan="4"></td>													
Stage III A $13.3\% (n=15)$ $7.1\% (n=8)$ Stage III B $27.6\% (n=31)$ $31.2\% (n=35)$ Stage III C $12.5\% (n=14)$ $8.03\% (n=9)$ Table 3: Operative time, blood loss, complicationsVariableOPEN $(n=60)$ LAP $(n=52)$ P valueOperative time140 minutes $174 minutes$ $0.0001$ Mange 121-243Range 136-302minutesminutesBlood loss125 ml (median)200 ml (median) $0.08$ Complications-YES 188 $0.06$ Complications-NO4244Table 4: RecurrenceVariableOPEN $(n=60)$ LAP $(n=52)$ P valueRecurrence-YES2017 $0.552$ Recurrence-NO4035 $35$ Table 5: DFSVariableEstimate95% CI (UL)95% CI (LL)P valueOPEN $(n=60)$ 77.671.15284.048 $0.524$													
Stage III B         27.6% (n=31)         31.2% (n=35)           Stage III C         12.5% (n=14)         8.03% (n=9)           Table 3: Operative time, blood loss, complications         Variable         OPEN (n=60)         LAP (n=52)         P value           Operative time         140 minutes         174 minutes         0.0001         (mean)         Range 136-302         0.0001           Range 121-243         minutes         125 ml (median)         200 ml (median)         0.08           Blood loss         125 ml (median)         200 ml (median)         0.08           Complications-YES         18         8         0.06           Complications-NO         42         44         44           Table 4: Recurrence           Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         5           Table 5: DFS         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524		_											
Stage III C12.5% (n=14)8.03% (n=9)Table 3: Operative time, blood loss, complicationsVariableOPEN (n=60)LAP (n=52)P valueOperative time140 minutes174 minutes0.0001(mean)(mean)(mean)Range 136-302minutesBlood loss125 ml (median)200 ml (median)0.08Complications-YES1880.06Complications-NO42440.06Table 4: RecurrenceVariableOPEN (n=60)LAP (n=52)P valueRecurrence-YES20170.552Recurrence-NO40355Table 5: DFSVariableEstimate95% CI (UL)95% CI (LL)P valueOPEN (n=60)77.671.15284.0480.524								( )					
Table 3: Operative time, blood loss, complications         P value           Variable         OPEN (n=60)         LAP (n=52)         P value           Operative time         140 minutes         174 minutes         0.0001           Range 121-243         Range 136-302         minutes         0.008           Blood loss         125 ml (median)         200 ml (median)         0.08           Complications-YES         18         8         0.06           Complications-NO         42         44         44           Table 4: Recurrence         Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552         0.552           Recurrence-NO         40         35         5         5           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524										)			
Variable         OPEN (n=60)         LAP (n=52)         P value           Operative time         140 minutes         174 minutes         0.0001           Range 121-243         Range 136-302         minutes         0.0001           Blood loss         125 ml (median)         200 ml (median)         0.08           Complications-YES         18         8         0.06           Complications-NO         42         44         44           Table 4: Recurrence           Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         5           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524													
Operative time         140 minutes (mean) Range 121-243 minutes         174 minutes (mean) Range 136-302 minutes         0.0001           Blood loss         125 ml (median) Range 50-650 ml         200 ml (median) Range 50-1000ml         0.08           Complications-YES         18         8         0.06           Complications-NO         42         44         44           Table 4: Recurrence         Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552         17           Recurrence-NO         40         35         5         5           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524	Table 3: Operat	tive	time,	blood lo	ss, c	om	plication	15					
Image 121-243 minutes       (mean) Range 121-243 minutes       (mean) Range 136-302 minutes         Blood loss       125 ml (median) Range 50-650 ml       200 ml (median) Range 50-1000ml       0.08         Complications-YES       18       8       0.06         Complications-NO       42       44       44         Table 4: Recurrence       0PEN (n=60)       LAP (n=52)       P value         Recurrence-YES       20       17       0.552         Recurrence-NO       40       35       5         Table 5: DFS       5% CI (UL)       95% CI (LL)       P value         OPEN (n=60)       77.6       71.152       84.048       0.524	Variable		OPEN	N (n=60)		LA	AP (n=52)	)		P value			
Range 121-243 minutes         Range 136-302 minutes           Blood loss         125 ml (median) Range 50-650 ml         200 ml (median) Range 50-1000ml         0.08           Complications-YES         18         8         0.06           Complications-NO         42         44         0           Table 4: Recurrence         44         0.552         0.552           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         0.052           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524	Operative time	140 m					S	0.0001					
minutes         minutes           Blood loss         125 ml (median) Range 50-650 ml         200 ml (median) Range 50-1000ml         0.08           Complications-YES         18         8         0.06           Complications-NO         42         44         0.06           Table 4: Recurrence           Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         5           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524													
Range 50-650 ml         Range 50-1000ml           Complications-YES         18         8         0.06           Complications-NO         42         44         44           Table 4: Recurrence           Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         5           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524	D1 11												
Complications-YES         18         8         0.06           Complications-NO         42         44         44           Table 4: Recurrence         Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         5           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524	Blood loss												
Complications-NO         42         44           Table 4: Recurrence         Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35						inge 50-1							
Table 4: Recurrence           Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35	Complications-Y						0.0						
Variable         OPEN (n=60)         LAP (n=52)         P value           Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         17           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524													
Recurrence-YES         20         17         0.552           Recurrence-NO         40         35         5           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524													
Recurrence-NO         40         35           Table 5: DFS         Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524							n=52)						
Table 5: DFS           Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524							0.552						
Variable         Estimate         95% CI (UL)         95% CI (LL)         P value           OPEN (n=60)         77.6         71.152         84.048         0.524	Recurrence-NO	4	0	35									
OPEN (n=60) 77.6 71.152 84.048 0.524	Table 5: DFS												
	Variable E	Variable Estimate			95% CI (UL) 95%			· /					
LAP (n=52) 81.6 75.348 88.037	OPEN (n=60) 7'								0.524				
	LAP (n=52) 8		75.348			88.037							



#### Figure 1 Showing OS







#### **DISCUSSION:**

Laparoscopic surgery for rectal cancer has been one of the emerging options in the management of rectal cancer. This study is specifically focused on node positive rectal cancers.

Matching was done on the basis of surgical approach. Patient background was ideally balanced in the groups by matching, and the comparison of open and laparoscopic surgery was considered reliable.

Laparoscopic colorectal surgery is an attractive option and been in use after multiple, large, randomized, controlled trials in colorectal cancer have showed that this approach is safe and with equal oncological results as open surgery. (11,13,14) Despite comparable cancer outcomes and postoperative rewards in laparoscopic surgery, most colorectal cancers are treated by open surgery. The main barrier to common implementation has been the technical difficulty of these Surgeries. (15) Laparoscopic rectal cancer surgery not only requires technical expertise of surgeons who demonstrate advanced laparoscopic techniques, but also skill experienced required in open surgery.

Operative time is the much-debated issue when laparoscopy came into practice. A recent metanalysis addressing this issue showed that the operative time is longer in the laparoscopy group when compared with open group. Average difference of 40 min was observed between the median operating time of two groups. Our study showed statistically significant difference between the two groups in terms of operating time. The median time for open surgery is 140 minutes and that of laparoscopic surgery is 174 minutes. The difference of time observed between the groups is 34 minutes. These results are similar to other studies which showed average difference of 40-50 minutes. (8,11) But there is marked heterogenicity observed reported by various authors in regard to difference in operative time between the laparoscopy and open groups. In a study by Araujo et al. the operative time for laparoscopy was shorter than open group. However small study sample of this study underpowered the result. Similarly, study by Stevenson et al., (10) showed the difference in operative time to be 20 minutes. However, the differences in operative times between the two groups may be lessened with increasing surgeon experience and advances in laparoscopic technology.

In previous studies, it was found that intraoperatively the amount of blood loss in laparoscopic surgery was significantly less than in the open surgery. (17) Even though measurement of intraoperative blood loss is tough to standardize, it is obvious that blood loss is minimal

because of high definition and large view and fine dissection in laparoscopic surgery. Our study showed no significant difference in terms of blood loss between the laparoscopic and open groups.

There is no significant difference between the post-operative complications between the two groups. This is supported by a recent meta-analysis which showed there are no significant differences in intra-operative complications, postoperative overall morbidity and specific complications (postoperative ileus, anastomotic leakage and mortality). (18)

In regard with the oncological outcomes, our study showed that circumferential margin positivity is observed in 15% of open surgery group and 8.3% of the laparoscopy group. There two groups are found to be statistically non-significant. Our study showed that there was no statistically significant difference between the 5-year DFS and OS between the laparoscopy and open groups. This evidence is supported by metanalysis which showed that were no significant differences in other postoperative complications, oncological clearance, 3-year and 5-year or 10-year recurrence and survival rates between two procedures. (19)

Our study has its limitations, as it is a retrospective series based on case records. A major drawback of this investigation is the limited detail available for each case. However, this study highlights that there is inherited difficulty in performing laparoscopic surgery for rectal cancer but this does translate into increased morbidity or compromise oncological outcomes.

### **CONCLUSION:**

Laparoscopic surgery has longer operative times than open surgery. However, laparoscopic and open have comparable equal efficacy in relation to post-operative complications, oncological outcomes. Laparoscopic rectal cancer surgery is technically feasible and outcomes are enhanced with expertise.

#### **REFERENCES:**

- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2
- Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, Mangone Francisci S, EUROCARE Working Group. Int J Cancer. 2012 Oct 1; 131(7):1649-58.
- 3 van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014:50:1.e1-34
- Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. 4. Lancet 2002; 359:2224-2229.
- COST group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350:2050–2059. Bonjer HJ, Haglind E, Jeekel I, et al. Laparoscopic surgery versus open surgery for colon 5.
- 6.
- Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): 7. multicentre, randomised controlled trial. Lancet 2005; 365:1718–1726. Kang SB, Park JW, Jeong SY, et al. Open versus laparoscopic surgery for mid or low
- 8. rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010; 11:637-645.
- 9. van der Pas MH, Haglind E, Cuesta MA, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013; 14:210-218.
- 10 Stevenson AR, Solomon MJ, Lumley JW, et al. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized
- vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA2015; 314:1356–1363. Fleshman J, Branda M, Sargent DJ, et al. Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA2015; 314:1346–1355. Toda S, Kuroyanagi H. Laparoscopic surgery for rectal cancer: current status and future perspective. Asian J Endosc Surg2014; 7:2–10. M. Buunen, R. Veldkamp, W. C. Hop et al., "Survival after laparo-scopic surgery versus 11.
- 12
- 13 Dourant, R. Forkamp, M. C. Inpetan, Supervisition of a randomised clinical trial," The Lancet Oncology, vol. 10, no. 1, pp. 44–52, 2009.
   T. Lourenco, A. Murray, A. Grant, A. McKinley, Z. Krukowski, and L. Vale,
- 14. "Laparoscopic surgery for colorectal cancer: safe and effective?—A systematic review," Surgical Endoscopy and other Interventional Techniques, vol. 22, no. 5, pp. 1146–1160, 2008
- L. L. Swanström and N. J. Soper, Eds., Mastery of Endoscopic and Laparoscopic 15. L. L. SWaitstoffi and N. J. Solper, Eds., Mastery of Encoscopic and Equiposcopic Surgery, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 4th edition, 2014. Araujo SE, da Silva eSousa AH, de Campos FG, et al. Conventional approach x
- 16 laparoscopic abdominoperineal resection for rectal cancer treatment after neoadjuvant chemoradiation: results of a prospective randomized trial. Rev Hosp Clin Fac Med Sao Paulo. 2003;58:133-40.
- J. D. Rea, M. M. Cone, B. S. Diggs, K. E. Deveney, K. C. Lu, and D. O. Herzig, "Utilization of laparoscopic colectomy in the United States before and after the clinical outcomes of surgical therapy study group trial," Annals of Surgery, vol. 254, no. 2, pp. 2014.000 17. 281-288, 2011.
- Małczak, P., Mizera, M., Torbicz, G., Witowski, J., Major, P., Pisarska, M., ... Pędziwiatr, M. (2018). Is the laparoscopic approach for rectal cancer superior to open surgery? A systematic review and meta-analysis on short-term surgical outcomes. Videosurgery and other miniinvasive techniques, 13(2), 129-140.
- Zhang F, Zhou Z, Wang H, Zhang J, Di B, Huang W et al. Laparoscopic Versus Open 19 Surgery for Rectal Cancer: A Systematic Review and Meta-analysis of Randomize Controlled Trials. Asian Pacific Journal of Cancer Prevention. 2014;15(22):9985-9996.

24